Physician profile
Walter L Chesshir
NPI 1043285836
$2,662.51
in general payments reported to CMS, 2019-2025
22 companies · $14.47 in 2025
The $14.47 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $114 · 2021: $511 · 2022: $636 · 2023: $1,057 · 2024: $125 · 2025: $14.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $509.14 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $507.78 | 2019-2023 | Farxiga, Lynparza |
| Abbott Laboratories | $204.95 | 2019-2024 | Freestyle Libre 3, Proclaim |
| Biohaven Pharmaceutical Holding Company LTD. | $189.62 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $177.34 | 2020-2021 | |
| Lilly USA, LLC | $174.69 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $139.86 | 2022-2023 | |
| Glaxosmithkline, LLC. | $126.69 | 2019-2024 | Trelegy Ellipta, Arexvy, Bexsero |
| Corium, LLC | $117.94 | 2022-2023 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.97 | 2019-2024 | Jardiance |
| Allergan, INC. | $80.64 | 2019-2022 | |
| Exact Sciences Corporation | $77.78 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $37.40 | 2021-2022 | |
| Antares Pharma, INC. | $36.17 | 2023 | Tlando, Xyosted, Nocdurna |
| Idorsia Pharmaceuticals US INC | $31.83 | 2023 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.42 | 2023 | |
| Sanofi-Aventis U.S. LLC | $22.50 | 2019 | |
| Currax Pharmaceuticals LLC | $16.49 | 2021 | |
| Amgen INC. | $14.23 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.66 | 2019 | |
| Vertiflex, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Chesshir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.